A recent preclinical study has shown that pretreatment of tumor-bearing mice with an adeno-associated viral vector expressing VEGF-B completely inhibits the doxorubicin-induced cardiac atrophy and whole-body wasting (93). This evidence concerns the gene VEGFB and neoplasm.